Patents Examined by Noble E Jarrell
  • Patent number: 10696645
    Abstract: Disclosed is a purified dialkyl furan dicarboxylate (DAFD) vapor composition containing at least 99.5 wt. % DAFD; 5-(alkoxycarbonyl) furan-2-carboxylic acid (ACFC) that, if present, is present in an amount of not more than 1000 ppm, alkyl-5-formylfuran-2-carboxylate (AFFC) that, if present, is present in an amount of not more than 1000 ppm, 5-(dialkoxymethyl)furan-2-carboxylic acid (DAFCA) that if present, is present in an amount of not more than 1000 ppm, and alkyl 5-(dialkoxymethyl)furan-2-carboxylate (ADAFC) that if present, is present in an amount of not more than 1000 ppm, in each case based on the weight of the DAFD vapor composition.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: June 30, 2020
    Assignee: Eastman Chemical Company
    Inventor: Mesfin Ejerssa Janka
  • Patent number: 10682341
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: STC.UNM
    Inventors: Eric R. Prossnitz, Matthias Barton, Matthias R. Meyer
  • Patent number: 10683275
    Abstract: The present application discloses a levelling compound for electrodepositing metals.
    Type: Grant
    Filed: April 20, 2019
    Date of Patent: June 16, 2020
    Assignee: SHINHAO MATERIALS LLC
    Inventors: Yun Zhang, Tao Ma, Peipei Dong, Zifang Zhu, Chen Chen
  • Patent number: 10682348
    Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 16, 2020
    Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES S.r.L.
    Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
  • Patent number: 10676442
    Abstract: The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 9, 2020
    Assignees: China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry
    Inventors: Meihua Xie, Fuli Zhang, Taizhi Wu, Jialiang Zhong
  • Patent number: 10676477
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yeheng Zhu, Andrew K. Dilger, William R. Ewing, Michael J. Orwat, Donald J. P. Pinto
  • Patent number: 10676449
    Abstract: Compounds of Formula I: wherein: R1 and R1? are independently selected from hydrogen, halogen, C1-to-C12 linear or branched hydroxyalkyl, C1-to-C12 linear or branched halo-alkyl, carboxy, carboxyalkyl, amido, N-alkylamido, N,N-dialkylamido, carbamoyloxy, N-alkylcarbamoyloxy, and N,N-dialkylcarbamoyloxy, provided that that R1 and R1? are not simultaneously hydrogen; R2 and R2? hydrogen, halogen, C1-to-C12 linear or branched hydroxyalkyl, C1-to-C12 linear or branched halo-alkyl, carboxy, carboxyalkyl, amido, N-alkylamido, N,N-dialkylamido, carbamoyloxy, N-alkylcarbamoyloxy, and N,N-dialkylcarbamoyloxy, provided that that R2 and R2? are not simultaneously hydrogen; R3 is selected from hydrogen, C1 to C12 linear or branched alkyl, and nitrogen protecting groups; X is oxygen or nitrogen; when X is oxygen, R4 is absent; and when X is nitrogen, R4 is selected from H, C1-to-C12 linear or branched alkyl, and nitrogen protecting groups.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 9, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jennifer M. Schomaker, Eileen G. Burke
  • Patent number: 10669248
    Abstract: Various aspects of this disclosure relate to methods to lower the activation energy of the cannabinoid decarboxylation reaction by performing the decarboxylation reaction in the gas phase.
    Type: Grant
    Filed: February 9, 2019
    Date of Patent: June 2, 2020
    Assignee: Natural Extraction Systems, LLC
    Inventors: C. Russell Thomas, Matthew M. DePalo
  • Patent number: 10668167
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: June 2, 2020
    Assignee: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
  • Patent number: 10662163
    Abstract: The present invention provides crystalline forms of compound of formula (Ia) and processes of making the crystalline forms.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 26, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Patent number: 10662261
    Abstract: The present invention relates to dimeric pentadentate chelators with exceptionally strong binding of metal ions, for detection, immobilization and purification of biomolecules. Dimeric chelators offer a cooperativity of binding of two adjacent immobilized metal ions simultaneously to a histidine-tagged biomolecule, which gives advantageous properties regarding strength of binding compared to a corresponding monomer chelator. In addition, a dimer increases the selectivity (ease of separation) against non-tagged biomolecules with low metal-ion affinity.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: May 26, 2020
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Mattias Algotsson, Lars C. Andersson, Eggert Brekkan, Lee Hedemyr, Jean-Luc Maloisel, Ronnie Palmgren
  • Patent number: 10654843
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 19, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • Patent number: 10654852
    Abstract: The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subject using such compounds.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 19, 2020
    Assignee: THE BROAD INSTITUTE, INC.
    Inventor: Joseph P. Vacca
  • Patent number: 10654848
    Abstract: Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, ?-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 19, 2020
    Assignees: Chang Gung University of Science and Technology, Chang Gung University, Kaohsiung Medical University
    Inventors: Tsong-Long Hwang, Yeh-Long Chen, Cherng-Chyi Tzeng, Chih-Hua Tseng
  • Patent number: 10656515
    Abstract: The present invention disclose photochromic metal organic frameworks (MOFs) containing photochromic 1,4,5,8-naphthalenediimide (NDI) core and metal ions selected from Mg, Ca or Sr. The developed MOFs find application in inkless and erasable printing wherein they retain the photogenerated colour for a prolonged period of time so that the printed content remains legible/readable for reasonable time.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: May 19, 2020
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Rahul Banerjee, Bikash Garai, Arijit Mallick
  • Patent number: 10647718
    Abstract: Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITÉDE MONTRÉAL
    Inventors: Guy Sauvageau, Yves Gareau, Stéphane Gingras
  • Patent number: 10647682
    Abstract: Provided are salts of 2,6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 12, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Runfeng Lin, Liang Chen, Xiaojun Wang, Yingjun Zhang, Jiancun Zhang
  • Patent number: 10647679
    Abstract: This disclosure relates to tetrahydroisoquinolines, salts, and derivatives useful for managing mental or cognitive diseases or conditions of the brain or central nervous system. In certain embodiments, the disclosure relates to compounds and compositions having formula I: prodrugs, esters, or salts thereof, wherein the substituents are described herein.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: May 12, 2020
    Assignee: Emory University
    Inventors: Katie L. Strong, David Menaldino, Dennis C. Liotta, Stephen F. Traynelis, Rose M. Freel, Matthew Epplin
  • Patent number: 10640504
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: May 5, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • Patent number: 10640524
    Abstract: The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 5, 2020
    Assignee: EPOS-IASIS RESEARCH AND DEVELOPMNT, LTD
    Inventors: Andreani Odysseos, Costas Pitris, Anastasios Keramidas